Search

OBJECTIVE: To explore the correlation of ABCB1 gene polymorphism and myelosuppression with taxanes application in breast cancer patients. METHODS: From Oct. 2019 to Dec. 2022, a total of 160 patients diagnosed with breast cancer in Affiliated Taian Central Hospital of Qingdao University were retrospectively analyzed. All patients were treated with a taxanes drug-based regimen. Univariate and Logistic regression were used to analyze the correlation with myelosuppression such as ABCB1 genotype. The correlation was analyzed by using gene stratification. Linkage disequilibrium effect of ABCB1 genotype was analyzed by SHEsis online software. RESULTS: Body mass index, ABCB1 G2677T genotype and molecular subtype had an effect on myelosuppression with significant difference (P< 0. 05). Compared with patients receiving taxanes for injection (albumin-bound), the incidences of moderate-to-severe myelosuppression (P = 0. 03), moderate-to-severe leukopenia(P = 0. 01) and moderate-to-severe neutrophilia (P<0. 05) were lower in liposomes of taxanes for injection; the incidence of myelosuppression in patients with ABCB1 2677TT genotype was higher than those with GT and GG genotypes (P < 0. 05), with statistically significant differences. There was linkage disequilibrium in ABCB1 loci, yet the difference between ABCB1 haplotypes and the occurrence of myelosuppressive in patients was not statistically significant (P> 0. 05). CONCLUSIONS: In patients with breast cancer, clinical assessment of adverse drug reactions of taxanes requires a comprehensive consideration of the patients' genotype and gene-gene interactions, in addition to body mass index, molecular subtype, and type of taxanes. [ABSTRACT FROM AUTHOR]

Antitumor drugs taxanes are widely used for the treatment of malignant tumors because of their remarkable biological activity and unique mechanism of action. Currently marketed taxanes include Paclitaxel injection, Paclitaxel liposome for injection, Paclitaxel for injection (albumin-bound), Paclitaxel polymeric micelles for injection and Docetaxel injection. Due to the differences in pharmacokinetics, pharmacodynamics and toxicology caused by the optimization of the structure and the innovation of dosage form, the pharmaceutical care for different taxanes is far from each other in many aspects. To standardized and rational use of taxanes, experts from the Cancer Pharmacists Branch of Chinese Pharmacists Association, together with multidisciplanry experts from around China and under the guidance of the National Cancer Center reached the Chinese Expert Consensus on the Pharmaceutical Care for Anti-tumor Drugs Taxanes through Delphi method and expert meeting based on clinical evidence, domestic law and regulations for pharmaceutical administration and pharmaceutical care practice. Through the consensus, the whole system of pharmaceutical care is constructed, with expanded and extended pharmaceutical care for anti-tumor drugs taxanes, which provides a scientific basis for pharmacists to carry out related pharmaceutical care. [ABSTRACT FROM AUTHOR]

The study was conducted to develop an efficient high performance liquid chromatography (HPLC) method for simultane)ous determination of seven taxanes in Taxus, the contents of seven taxanes in three Taxus species were compared and analyzed. HPLC detection conditions were: the chromatographic column was HiQsil C18 column; the binary mobile phases was acetonitrile (A)-water (B); the gradient elution procedure was (0~ 10 min,30%A;10~ 12 min,30% ~ 45%A;12 ~ 25 min,45%A;25 ~ 30 min,42% ~ 45% A;30~ 40 min,30% ~ 42%A); the detection wavelength was 227 nm. Linear regression was carried out for the mass concentration and peak area of each taxane component, and the sample recovery of 7 taxanes at different addition levels was investigated. The results showed that the contents of paclitaxel in the bark of Taxus cuspidata, Taxus chinensis var. mairei and Taxus×media cv. hicksii were 0. 234, 0. 043, 0. 167 mg / g, the contents of Taxol B were 0. 092, 0. 034, 0. 053 mg / g, the contents of 10-DAB were 0. 376, 0. 158, 0. 063 mg / g, the contents of 10-DAT were 0. 157, 0. 113, 0. 126 mg / g, the contents of Baccatin Ⅲ were 0. 395, 0. 116, 0. 074 mg / g, the contents of 7-epi-10-DAT were 0. 053, 0. 027, 0. 033 mg / g, the contents of 7-xyl-10-DAT were 0. 266, 0. 564, 0. 315 mg / g. Tax)anes in Taxus cuspidata were the highest, followed by Taxus cuspidate, and the lowest in Taxus×media cv. hicksii. The seven taxane compounds had good linear relationship within the linear range determined, and the test results of sample addition recovery rate showed that the recovery rate of this method was high. The established HPLC analysis method can simultaneously determine the contents of sev)en taxanes in Taxus, and this study provides a basis for the quality control, provenance breeding and resource development of Taxu [ABSTRACT FROM AUTHOR]

Taxanes are cornerstones of cancer chemotherapy and can he used for the treatment of various tumors, including breast cancer. Taxane-associated peripheral neuropathy is a common adverse effect of taxanes, leading to discontinuation of drug therapy, affecting drug treatment outcomes, and severely affecting patients quality of life. This consensus addresses and recommends the pathogenesis, clinical features, associated risk factors, diagnostic evaluation, prevention, and treatment of tax

Breast cancer is the most common malignant tumor among women. Taxanes are one of the most frequently used chemotherapy regimens for breast cancer. In order to guide clinicians rational use of taxanes mid further standardize the diagnosis mid treatment of breast cancer, the expert group proposed this "Expert consensus on the clinical practice of taxanes for the treatment of breast cancer" based on substantial evidence and thorough discussion. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common malignant tumor among women. Taxanes are one of the most frequently used chemotherapy regimens for breast cancer. In order to guide clinicians rational use of taxanes and further standardize the diagnosis and treatment of breast cancer, the expert group proposed this "Expert consensus on the clinical practice of taxanes for the treatment of breast cancer" based on substantial evidence and thorough discussion.